News

BenevolentAI at NeurIPS 2020: Machine Learning in Drug Discovery

BenevolentAI will be proudly sponsoring NeurIPS again this year. Here are the details of our activities during the week:

Expo day: 6th December

How we leverage machine learning and AI to develop life-changing medicines - a case study with COVID-19.

The model for drug discovery and development is failing patients. It is expensive and high risk, with long research and development cycles. In this talk, we will discuss the peculiarities of machine learning across drug discovery, from the processing of scientific literature, to knowledge completion, target identification to precision medicine, to chemistry optimisation, each leveraging domain expert knowledge and state-of-the-art research and we will conclude our talk with a real example which will showcase the application of our technology and scientific expertise to repurpose existing drugs, as a potential treatment for COVID-19. 

Expo Schedule →

Meetup: 8th December

Application of Machine Learning to Drug Discovery Meetup

Why is drug discovery so complex? How can ML help to solve these scientific challenges? What does an ML applied drug discovery model look like? What skills are useful to the industry? If you are asking yourself some of these questions, then this meetup is for you.

Save your spot →


Our Research at NeurIPS

Learning Meaningful Representations of Life workshop:

Our AI Science Intern, Constantin Schneider, will present his paper on ‘Auxiliary task evaluations to learn meaningful representations from electronic health records', co-authored by BenevolentAI's Senior Machine Learning Researcher, Hamish Tomlinson, at the Learning Meaningful Representations of Life workshop.

Authors: Hamish Tomlinson, Constantin Schneider

----

Machine Learning for Molecules Workshop

Our team will be presenting their paper on 'Molecular representation learning with language models and domain-relevant auxiliary tasks' at the Machine Learning for Molecules Workshop.

Authors: Fabian et al. (2020)



Network with our team: join us on Hopin

While you're at NeurIPS, connect with our team virtually via the Hopin platform. Connect with our team at networking sessions to ask any questions you may have, and/or join our careers with impact meetup to learn more about what we do and how we work. The full programme will be coming soon. As we have limited space, we advise you to book your spot now.

Save your spot → Neurips Expo → Talent Pool →
More Posts

You Might Also Like

Video
Data & Digital Innovation for Climate & Health
Joanna Shields, CEO BenevolentAI, joined the Wellcome Trust Panel at the World Economic forum to discuss opportunities for data and digital innovation to impact positively climate and health.
Jan 26, 2023
News
BenevolentAI submits CTA for BEN-8744, an oral PDE10 inhibitor, as a first-in-class treatment for ulcerative colitis
BenevolentAI submits clinical trial application for BEN-8744, with a Phase I clinical trial planned for H1 2023.
Dec 21, 2022
News
BenevolentAI to present at 41st Annual J.P. Morgan Healthcare Conference
BenevolentAI ​​(Euronext Amsterdam: BAI), a leading clinical-stage AI drug discovery company, announces that it will participate in the upcoming 41st Annual J.P. Morgan Healthcare Conference in San Francisco, US from 9-12 January 2023.
Dec 1, 2022
Blog
FAIR Data Foundation: An Enabler for AI Drug Discovery
Biomedical data used in AI-enabled drug discovery should adhere to the FAIR Data Principles — Findability, Accessibility, Interoperability and Reusability. This blog explains why this is, how one can make data FAIR and challenges that remain.
Nov 8, 2022
News
BenevolentAI to present at Jefferies Investor Conference in November
BenevolentAI’s Investor Relations and Business Development team will be attending the Jefferies Healthcare London conference, with Nick Keher, CFO, presenting on Thursday 17th November.
Nov 4, 2022
News
BenevolentAI achieves further milestones in AI-enabled target identification collaboration with AstraZeneca
Two additional AI-generated novel targets selected by AstraZeneca for its drug development portfolio, resulting in two milestone payments for BenevolentAI.
Oct 6, 2022